Guangzhou Kanglixin Medical Biotechnology

Guangzhou Kanglixin Medical Biotechnology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, focused on the development of novel small molecule targeted therapies for cancer. The company leverages its expertise in medicinal chemistry and oncology to create a pipeline of precision medicines, with a primary emphasis on kinase inhibitors. Its lead program, KLX-0702, is currently in Phase 1 clinical development for the treatment of advanced solid tumors. Kanglixin aims to address significant unmet needs in the oncology space by developing high-potency, low-toxicity drug candidates. The firm operates out of the Guangzhou Science City, integrating research, development, and clinical operations.